TNF and disease arising from reactivation of latent virus: In particular, anti‐TNF‐α agents, which reduce the production of TNF‐α by macrophages, where mycobacteria survive during LTBI, increase the risk of TB reactivation, mostly resulting from the reactivation of a latent infection [13].